Clinical Trial Update: Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy study of Lebrikizumab in adults and adolescents with moderate-to-severe Atopic Dermatitis is ongoing (Active, Not Recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Almirall, S.A. | Conditions: Atopic Dermatitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING